HCV ANTIVIRAL TESTING IN CHIMPANZEES

这个子项目是许多利用资源的研究子项目之一 由NIH/NCRR资助的中心拨款提供。子项目的主要支持 而子项目的主要调查员可能是由其他来源提供的， 包括其它NIH来源。 列出的子项目总成本可能 代表子项目使用的中心基础设施的估计数量， 而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。 大约2%的美国人口慢性感染丙型肝炎病毒（HCV）。慢性HCV感染导致严重的肝脏疾病，包括肝硬化和肝癌，约20%的感染者。目前的干扰素和利巴韦林治疗在大多数情况下不能清除病毒。开发改进的抗病毒策略来治疗HCV慢性感染对于控制这种疾病至关重要。本研究的目的是测试一系列小分子抗病毒HCV复制抑制剂在慢性感染HCV的黑猩猩中的疗效。该研究检查了几种不同类型抑制剂的抗病毒活性，并且在PK和疗效研究中检查了每一类抑制剂

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Approximately 2% of the U.S. population is chronically infected with hepatitis C virus (HCV). Chronic HCV infections result in significant liver disease, including cirrhosis and liver cancer in approximately 20% of infected individuals. The current therapy of interferon and ribavirin does not result in viral clearance in the majority of cases. The development of improved antiviral strategies to treat HCV chronic infection is essential for the control of this disease. The objective of this study is to test a series of small molecule antiviral inhibitors of HCV replication for efficacy in chimpanzees chronically infected with HCV. The study has examined antiviral activity from several different classes of inhibitors, and each of the classes has been examined in both PK and efficacy studies